Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma

Launched by INSTITUTE OF HEMATOLOGY & BLOOD DISEASES HOSPITAL, CHINA · Jul 14, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for patients who have not yet received any therapy for Nodal T-follicular Helper (TFH) Cell Lymphoma, a type of cancer affecting the lymphatic system. The treatment combines two medications, chidamide and azacitidine, which will be given over several cycles to see how well they work in helping patients achieve a complete response (CR) or a partial response (PR). Depending on how well patients respond to the initial treatment, they may continue with more cycles of the same medications or receive additional therapies to help maintain their improvement.

To participate in this trial, patients must be over 18 years old and have a confirmed diagnosis of nodal TFH cell lymphoma. They should also be in good overall health, with properly functioning organs and no prior treatments for cancer. Participants can expect to receive the study medications for a specific period, along with regular evaluations to track their progress. It's important to note that patients with certain health conditions or those who have previously been treated for cancer may not be eligible to join the study. This trial is currently recruiting participants, and those who are interested should speak with their healthcare provider for more details.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Subjects must have histological confirmation of nodal T-follicular helper (TFH) cell lymphoma.
• • 2. More than 18 years of age.
• • 3. Proper functioning of the major organs: 1) The absolute value of neutrophils (≥1×10\^9/L); 2) platelet count (≥75×10\^9/L); 3) Serum total bilirubin ≤ 1.5 times ULN; 4) Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) ≤3 times ULN; 5) Serum creatinine (Cr) ≤2 ULN, or glomerular filtration rate ≥40ml/min;
• • 4. Eastern Cooperative Oncology Group (ECOG) Performance status 0-2.
• • 5. LVEF value measured by echocardiography ≥50%.
• • 6. Life expectancy \> 3 months.
• Exclusion Criteria:
• • 1. Patients who have previously received chemotherapy, radiotherapy or other antitumor therapy.
• • 2. Patients with central nervous system involvement by lymphoma.
• • 3. Patients with uncontrolled cardiovascular and cerebrovascular diseases, coagulation disorders, connective tissue diseases, serious infectious diseases and other diseases.
• • 4. Pregnant or breastfeeding women.
• • 5. Presence of human immunodeficiency virus (HIV) virus infection.
• 6. Previous history of other malignant tumors, unless the disease has been cured for 5 years or more. The following cured tumors are excluded:
• • 1. Basal cell carcinoma of the skin, squamous cell carcinoma of the skin and related localized non-melanoma skin cancers;
• • 2. Carcinoma in situ of the cervix